Ablation of the Chaperone Protein ERdj5 Results in a Sjögren’s Syndrome-Like Phenotype in Mice, Consistent With an Upregulated Unfolded Protein Response in Human Patients

Eirini Apostolou 1,2†, Petros Moustardas 3,4†, Takao Iwawaki 5, Athanasios G. Tzioufas 1,2‡ and Giannis Spyrou 3‡

1 Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2 Academic Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 3 Division of Microbiology and Molecular Medicine, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, 4 Department of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, 5 Division of Cell Medicine, Department of Life Science, Medical Research Institute, Kanazawa Medical University, Uchinada, Japan

Objective: Sjögren’s syndrome (SS) is a chronic autoimmune disorder that affects mainly the exocrine glands. Endoplasmic reticulum (ER) stress proteins have been suggested to participate in autoimmune and inflammatory responses, either acting as autoantigens, or by modulating factors of inflammation. The chaperone protein ERdj5 is an ER-resident disulfide reductase, required for the translocation of misfolded proteins during ER-associated protein degradation. In this study we investigated the role of ERdj5 in the salivary glands (SGs), in association with inflammation and autoimmunity.

Methods: In situ expression of ERdj5 and XBP1 activation were studied immunohistochemically in minor SG tissues from primary SS patients and non-SS sicca-complaining controls. We used the mouse model of ERdj5 ablation and characterized its features: Histopathological, serological (antinuclear antibodies and cytokine levels), and functional (saliva flow rate).

Results: ERdj5 was highly expressed in the minor SGs of SS patients, with stain intensity correlated to inflammatory lesion severity and anti-SSA/Ro positivity. Moreover, SS patients demonstrated higher XBP1 activation within the SGs. Remarkably, ablation of ERdj5 in mice conveyed many of the cardinal features of SS, like spontaneous inflammation in SGs with infiltrating T and B lymphocytes, distinct cytokine signature, excessive cell death, reduced saliva flow, and production of anti-SSA/Ro and anti-SSB/La autoantibodies. Notably, these features were more pronounced in female mice.

Conclusions: Our findings suggest a critical connection between the function of the ER chaperone protein ERdj5 and autoimmune inflammatory responses in the SGs and provide evidence for a new, potent animal model of SS.

Keywords: ERdj5, ER-stress, autoimmunity, salivary gland, Sjögren’s syndrome, XBP1, UPR
INTRODUCTION

The Endoplasmic Reticulum (ER) is the site responsible for the proper folding, processing, and trafficking of membrane-bound and secreted proteins. This task is accomplished by a system of ER resident proteins that collectively constitute the ER protein quality control system (ERQC) (1). The ER can respond to stimuli such as accumulation of misfolded proteins and metabolic signals in a condition termed ER-stress, by the activation of the Unfolded Protein Response (UPR) (2). The UPR is an adaptive mechanism comprised of three signaling axes, the IRE1α/XBP1, the PERK/eIF2α, and the ATF6 axis, which are regulated by a common ER resident sensor molecule, BiP. Upon stimulation by excessive misfolded protein load in the ER, IRE1α homodimerizes, and trans-autophosphorylates, causing the alternative splicing of XBP1 to XBP1s, with the latter being a transcription factor that binds directly to stress regulated promoters in the nucleus and controls the expression of many ER-stress related genes. Similarly, activation of the other two branches of the UPR results in the release of the transcription factors CHOP and ATF6p50. Collectively, they promote translation attenuation, ER expansion, enhanced proteolysis and, in unresolved ER-stress cases, inflammation, autophagy, and apoptosis. Deviation from ER homeostasis and activation of the UPR have been implicated in various pathogenic processes of autoimmune diseases, although the mechanism underlying such effects remains largely unknown.

One important aspect linking ER-stress to immune responses is the intersection of UPR and inflammatory signaling, including NF-κB activation, Toll-like receptor signaling and stress kinase signaling (3). UPR signaling plays a role in T cell development and in antigen-triggered B cell differentiation into immunoglobulin producing plasma cells. Moreover, the constitutively active IRE1α/XBP1 axis in mature and immature dendritic cells (DCs) and natural killer (NK) cells is crucial for their development, survival, and function (4). The connection between inflammation and protein misfolding is evident in diseases like TNF receptor-associated periodic syndrome (TRAPS), where mutated, misfolding TNF receptor, and its accumulation in the ER have been linked to the disease (5).

ER-stress and autoimmunity in particular, have been linked through the differential expression of several ER-stress markers. Transcription factors and other markers indicative of ER-stress, such as IRE1α, CHOP, PERK, and XBP1, have been found to be deregulated in systemic lupus erythematosus (SLE) and scleroderma (SSc) (6), XBP1 mutations or deletions in animal models have been associated with inflammatory bowel disease (IBD) (7), and impaired ER-Golgi transport has been associated with lupus nephritis and rheumatoid arthritis (RA) (8).

Primary SS (pSS) is a chronic autoimmune disease characterized by both local exocrinopathy in the salivary gland (SG) and systemic manifestations that affect parenchymal organs. Importantly, 5–10% of SS patients develop B cell non-Hodgkin’s lymphoma (9). In human minor SGs (MSGs) from SS patients, pro-inflammatory cytokines have been suggested to perpetuate inflammatory responses and establish a chronic ER-stress state (10), which can lead to autophagy and differential distribution of autoantigens (11). Also, the IRE1α/XBP1 branch of the UPR is differentially regulated in Labial SGs (LSGs) of SS patients, in a manner consistent with chronic ER-stress (12).

ERdj5 is an ER-resident chaperone protein with very potent disulfide reductase and isomerase activity, expressed in secretory cells or following ER-stress (13). ERdj5 has been demonstrated to be a key molecule for the processing of misfolded proteins in the ER. It can bind to BiP with its J domain and enable the reduction of non-native disulfide bonds (14). Among the described functions of ERdj5 are the regulation of ER Ca2+ homeostasis (15), the facilitation of the correct folding of the LDL receptor (16), the sensitization of neuroblastoma cells to ER-stress-induced apoptosis (17) and the disulfide reduction of misfolded proteins, in order to enable their translocation from the ER to the cytosol during ER-associated protein degradation (ERAD) (18). In the salivary glands in particular, ERdj5 has been shown to contribute in ER protein quality control, since its ablation in mice results in an activated ER-stress response, evident by the upregulation of the alternatively spliced form of XBP1 within the SGs (19).

Given the established interplay between autoimmunity and ER function, and the fact that ERdj5 has an essential role in secretory cells like in the SGs, we aimed to investigate its role in the inflammatory lesions of SGs in the context of pSS. Moreover, we have studied the effects of ERdj5 ablation on the SGs of a mouse model deficient in ERdj5.

MATERIALS AND METHODS

Patients

Thirty female patients with pSS, and 12 non-SS sicca-complaining women (CT) were included in the study. Each patient underwent an MSG biopsy for SS diagnosis. Tissue biopsies of minor salivary gland lobules from patients were obtained from the inner side of the lower lip after local anesthesia. Paraffin sections of these biopsies were used along with acquired blood samples for SS diagnosis. A collection of the remaining sections were used in this study with informed consent from each patient. Patients were diagnosed by the American–European classification criteria (20) and were further categorized according to the grade of MSG inflammatory infiltration in those with mild (SS-I, n = 10; Tarpley score: 1, 1–2 focal infiltrates per lobule), intermediate (SS-II, n = 9; Tarpley score: 2+, ≥3 focal infiltrates per lobule) and severe lesions (SS-III, n = 11; Tarpley score: 3+, diffuse infiltrates associated with severe destruction of acinar glandular structures and loss of tissue architecture) (21). The biopsies from patients whose diagnosis was negative for SS were used as the control group in this study. All but one of those biopsies were totally devoid of inflammatory lesions. In all SS patients, the biopsy focus score (lymphocytic foci/4 mm² of tissue) was ≥1. All non-SS sicca-complaining patients had biopsy focus score <0.25, while after >5 years, none had had a newer, positive diagnosis.

The exclusion criteria for SS patients were the evidence of lymphoma, sarcoidosis or infection by hepatitis B, hepatitis C or human immunodeficiency virus, and treatment with biological agents before biopsy. The clinical characteristics of the SS
patients included in this study are summarized in Table 1. The patient study was approved by the Ethics Committee of the School of Medicine, National University of Athens, Greece (Protocol no. 5107).

Mouse Model
For the experimental evaluation of the role of ERdj5 in SS, we utilized the mouse model of 129SV ERdj5 Knockout mice (ERdj5<−/−, cohort designation: KO) and their respective 129SV wildtype controls (cohort designation: WT). This mouse model has been produced by the deletion of the exon containing the start codon for ERdj5 translation, producing mice unconditionally deficient in ERdj5 (19). The study cohorts included male or female mice of three age groups, 1.5, 7, and 12 months old (m.o.); 12 experimental groups: Male/Female x 1.5 m.o/7 m.o./12 m.o. x WT/KO. Depending on litter size for each age-matched pair of groups, the sample size was between 7 and 10 animals per animal group. Mice were maintained under monitored, pathogen free conditions in the experimental animal facility of the Biomedical Research Foundation of the Academy of Athens. The housing environment was set at temperature of 22–23°C, 45–55% humidity, a 12:12 h light/dark cycle with lights on at 07:00 a.m. Animals were given free access to drinking water and standard chow diet. The animal experiments were approved by the Animal Care and Use Committee, Veterinarian Administration, Attiki prefecture (Protocol no. K/1279/11).

Morphometric Analysis of ERdj5 and XBP1s Staining in Human MSGs
The in situ expression of ERdj5 and XBP1s in human MSGs was visualized immunohistochemically. In this study, we used four lobules from each patient, all paraffin embedded and sectioned under the same microscopy slide. For ERdj5, the positive staining and signal intensity in the whole tissue surface and in the secretory ductal epithelium of MSGs were quantitatively measured (see Supplemental Methods). Values were expressed as a percentage of the total tissue area and average stain intensity of positive pixels. For XBP1s, which gave an exclusively nuclear staining, positively stained nuclei were counted in the total tissue area and measurements were conducted with automated custom-built scripts for Image J (v.1.56j; FIJI distribution) software.

Histological and Immunofluorescence Examination of Mouse SGs
Tissue samples of whole submandibular salivary glands were obtained from all animal groups. For the morphometric analysis of the inflammatory lesions, lymphocytic infiltrations were defined as aggregates of >50 leucocytes and measured with the use of Image J software on images covering the entire area of the tissue section. Immunofluorescence staining on different sections of the same tissues was performed in order to visualize T cells, B cells, and macrophages (CD3, B220, F4/80, respectively) within the lesions.

Detection of Antinuclear Antibodies (ANAs) in Murine Serum
Anti-nuclear antibodies were detected in blood sera of mice using the HEp-2 ANA kit (Inova Diagnostics, San Diego, CA, USA). All procedures were performed according to the manufacturer’s instructions (see Supplemental Methods). Quantitative measurement of anti-SSA/Ro52, anti-SSA/Ro60, and anti-SSB/La in the murine serum was performed with ELISA assays (Signosis, Santa Clara, CA, USA). All procedures were performed according to the manufacturer’s instructions (see Supplemental Methods).

in situ Cell Death Assay
Cell death within murine SGs was evaluated using the TUNEL method (see Supplemental Methods) with the use of the terminal transferase recombinant kit (Roche Diagnostics GmbH) and Alexa Fluor568-conjugated dUTPs (Molecular Probes, MA, USA).

Salivary Gland Function
Saliva flow was measured on both sexes of KO and WT 12 months old animals, after stimulation by IP injection of pilocarpine solution. The total volume of secretion over time was recorded (see Supplemental Methods) and saliva secretory flow rate was calculated as the volume of saliva per g of mouse weight as a function of time required for each collection.

Cytokine Levels in Murine Serum and Salivary Glands
Levels of the murine cytokines IFN-γ, IL-1α, IL-2, IL-10, IL-17A, IL-18, IL-23, and TNF-α were measured both in sera and protein lysates of submaxillary glands using the ProcartaPlex Multiplex Immunoassay Magnetic bead panel (Invitrogen, Carlsbad, CA, USA) and a Luminex100 instrument according to the manufacturer’s instructions (see Supplemental Methods).

Statistical Analysis
The unpaired two-tailed non-parametric t-test was used for the comparison between experimental groups vs. controls, either in clinical samples or murine experimental data. For the comparison between multiple patient groups of differing lesion severity and multiple animal subgroups of various sexes and ages, we used one-way ANOVA with Tukey’s test correction for multiple comparisons. All statistical calculations were performed using the GraphPad Prism v.6.05 software. For all analyses, a p-value <0.05 was considered significant.

RESULTS

ERdj5 Is Expressed in Human MSGs and Was Upregulated in MSGs of SS Patients With Severe Inflammatory Lesions
Immunohistochemical analysis showed that ERdj5 is expressed in the MSGs of both SS patients and non-SS sicca-complaining
controls. Positive ERdj5 staining was observed in the ductal and acinar epithelium and in the infiltrating mononuclear cells (MNCs) (Figure 1A). Analysis of the stain intensity within the positively stained areas showed that the signal for ERdj5 was stronger in SS patients (Figure 1B, left panel; CT vs. SS: 16.4 ± 6.6 vs. 20.6 ± 0.7, t-test p = 0.0125). Comparison between lesion severity subgroups revealed that the ERdj5 positive signal was higher with increasing lesion severity (ANOVA p = 0.0052; CT vs. SS p = 0.0069, CT vs. SS-II p = 0.0152, CT vs. SS-III p = 0.0008, SS-I vs. SS-III p = 0.0084). This signal was localized within the inflammatory lesions (Figure 1B, middle panel; ANOVA p = 0.0011; SS-I vs. SS-II p = 0.0003, SS-I vs. SS-III p = 0.0014) and the ductal epithelium (Figure 1B, right panel; ANOVA p = 0.0071; CT vs. SS p = 0.0037, SS-I vs. SS-III p = 0.0259). Significant difference in ERdj5 staining intensity also emerged between patients negative or positive for anti-SSA/Ro (Figure 1C, upper panel; Negative anti-SSA/Ro vs. positive anti-SSA/Ro t-test p = 0.037: 18.49 ± 1.42, n = 11 vs. 21.63 ± 0.78, n = 18), while no statistically significant difference emerged when patients were classified according to anti-SSB/La serum reactivity (Figure 1C, lower panel).

**Sjögren’s Syndrome Patients Have Elevated ER-Stress in the Salivary Glands**

Staining of patient salivary gland biopsy sections for spliced XBP1 (Figure 2) revealed that SS patients have elevated levels of UPR activation, as evident by the higher percentage of nuclei that are positive for XBP1s within the tissue (CT vs. SS t-test p = 0.025: 4.05 ± 0.45%, n = 7 vs. 9.31 ± 1.31%, n = 19). Further analyzing the results according to disease severity revealed that the elevated XBP1s positive nuclei count was evident in the SS-II and SS-III groups, with SS-I not presenting a difference compared to CT (ANOVA p = 0.0106; CT vs. SS-I p = 0.908, CT vs. SS-II p = 0.0308, CT vs. SS-III p = 0.0402). The positively stained

---

**TABLE 1 | Clinical characteristics of the individuals included in the study.**

| Features | Non-SS sicca controls | SS patients |
|----------|------------------------|-------------|
| General  |                        |             |
| Age (years), median (range) | 55 (37–74) | 55 (18–74) |
| No of SS criteria fulfilled, median (range) | 1 (1–3) | 4 (3–6) |
| Duration (years) of sicca symptoms, median (range) | 5 (4–6) | 3 (0.33–17) |
| Histological (MSG biopsy) | 2.35 (1–6.91) | 1.18 (1–1.44) |
| Biopsy focus score (number of lymphocytic foci/4 mm²), median (range) | 0 (0–0.25) | 2.4 (1.6–3.75) |
|Tarpley biopsy score, median (range) | 0 (0–2) | 1 (1–4) |
| Clinical |                        |             |
| Arthralgias (%) | 50.0% | 32.4% |
| Arthritis (%) | 25.0% | 5.6% |
| SG enlargement (SGE) (%) | 8.3% | 24.3% |
| Reynaud’s phenomenon (%) | 8.3% | 39.4% |
| Parenchymal organ involvement (%) | 8.3% | 3.3% |
| Lung involvement (%) | 8.3% | 0.0% |
| Renal involvement (%) | 0.0% | 0.0% |
| Liver involvement (%) | 0.0% | 0.0% |
| Indicative of vasculitis involvement (%) | 0.0% | 0.0% |
| Palpable purpura (%) | 0.0% | 0.0% |
| Vasculitis (%) | 0.0% | 0.0% |
| Peripheral neuropathy (%) | 0.0% | 0.0% |
| Lymphoma (%) | 0.0% | 0.0% |
| Laboratory |                        |             |
| Anti-Ro/SSA and/or La/SSB positive (%) | 0.0% | 63.3% |
| Anti-Ro/SSA positive (%) | 0.0% | 58.1% |
| Anti-La/SSB positive (%) | 0.0% | 32.3% |
| Rheumatoid factor positive (%) | 16.7% | 38.2% |
| C3-levels, median (range) | 11 (74–171) | 95 (63–181) |
| C4-levels, median (range) | 26.5 (12–43) | 23.1 (7.5–47) |
| Cryoglobulinemia (%) | 0.0% | 5.3% |
| Hypergammaglobulinemia (%) | 0.0% | 29.7% |
| Leukopenia (%) | 0.0% | 5.6% |
| ESSDAI score | NA | 3 (0–9) |
nuclei were distributed within the tissue in a distinct pattern: Myoepithelial cells were sparsely positive in both control subjects and SS patients, with the latter having a higher percentage of positive cells. In the SS group, small inflammatory foci had a homogeneous distribution of positive cells within the lesion. In contrast, the large inflammatory infiltrations had an outer layer of densely positive cells, with the vast majority of the cells in the center negative. Rare mucous and serous cells were positive in SS patients, while the ductal epithelial cells were negative for XBP1s staining (Figure 2A).

ERdj5−/− Mice Develop Spontaneous Periductal Inflammation in SGs

The earliest evidence of inflammation was observed already from 6 weeks (in female KO mice) and the grade and severity of the inflammatory lesions developed over age (Figure 3A), as assessed by the quantitative analysis of inflammation area (Figure 3B; Male panel: 7 m.o. WT vs. KO t-test $p = 0.0032$, Female panel: 7 m.o. WT vs. KO t-test $p = 0.0332$, 12 m.o WT vs. KO t-test $p = 0.0004$) and inflammatory foci (Figure 3C; Male panel: 7 m.o. WT vs. KO t-test $p = 0.0004$, 12 m.o. WT
younger ages, anti-SSB/La autoantibodies were significantly elevated at 7 months compared to 1.5 months regardless of sex or genotype, but there were no detectable differences between WT vs. KO groups of the same age. Interestingly, male mice did not reveal any significant difference at any age regarding anti-SSA/Ro52 and anti-SSA/Ro60, but the 12 months old KO group had significantly lower amounts of anti-SSB/La compared to wildtypes (anti-La male ANOVA \( p < 0.0001 \): 12 m.o. WT vs. 12 m.o KO \( p = 0.0105; 0.424 \pm 0.059, n = 8 \) vs. 0.207 \pm 0.024, \( n = 6 \)).

**Cytokine Signature in the Serum and in Submaxillary Glands of ERdj5\(^{−/−}\) Mice**

Cytokine levels that were found to be deregulated in the blood sera of KO mice are illustrated in Figure 5A (the rest of the examined cytokines, IFN-\(\gamma\), IL-1\(\alpha\), IL-2, and TNF-\(\alpha\) were either at undetectable levels or not differing between groups). IL-18 was significantly higher in the serum of 12 month old female KO animals compared to both their respective controls and to the younger, 1.5 m.o. KO animals (12 m.o. WT vs. KO \( p = 0.0164, 1.5 \) m.o. KO vs. 12 m.o. KO \( p = 0.0218 \)). IL-23 was found to be significantly upregulated in the female KO group at 7 and 12 months of age, compared to the respective controls (ANOVA \( p = 0.0036; p < 0.05 \) in all comparisons of group 7 m.o. KO with groups 7 m.o. WT, 1.5 m.o. KO, and 12 m.o. KO). IL-17A was upregulated at 12 months of age in male KO animals (ANOVA \( p = 0.008; p < 0.02 \) in all comparisons of group 12 m.o. KO with groups 12 m.o. WT, 1.5 m.o. KO, and 7 m.o. KO).

Within the SGs of male animals, IL-18 was significantly higher in the tissue of 7 m.o. KO mice compared to age matched wildtype animals (ANOVA \( p < 0.0001 \)). Nevertheless, such a result did not emerge in the female groups. In WT animal SGs, IL-23, and IL-10 exhibited a pattern of reducing concentration with age. Interestingly, in the female KO mice this was not the case, intermediate levels of IL-10 and IL-23, were retained throughout all age groups (Figure 5B). As a result, IL-10 was found at significantly lower levels in the KO animals in a young age. For the same reason, in the 12 months old female animals,
IL-10 and IL-23 were significantly higher in the KO group, when compared to their age-matched controls (Figure 5B; IL-23 female panel: 12 m.o. WT vs. KO $p = 0.0183$, IL-10 female panel: ANOVA $p = 0.0004$; 1.5 m.o. KO vs. 1.5 m.o. WT $p = 0.0044$, 12 m.o. KO vs. 12 m.o. WT $p = 0.0143$).

**Enhanced Cell Death in the Submaxillary Glands of ERdj5$^{-/-}$ Mice**  
Within the SGs of KO mice, TUNEL positive material was prominent both in inflammatory infiltrates scattered throughout the lesions and in acinar epithelial cells and was more
Apostolou et al. ERdj5 Is Involved in Sjögren's Syndrome

**FIGURE 4** | Autoantibodies in the ERdj5−/− animal sera. (A) Serum concentrations of anti-nuclear antibodies (ANAs) in female (top panel) and male (bottom panel) ERdj5−/− mice and wildtype controls at 1.5, 7, and 12 months of age. (B) Detection of specific autoantibodies in the serum of female (top panels) and male (bottom panels) ERdj5−/− mice and wildtype controls at 1.5, 7, and 12 months of age. Left panels: detection of anti-SSA/Ro52 autoantibodies; Middle panels: detection of anti-SSA/Ro60 autoantibodies; Right panels: detection of anti-SSB/La autoantibodies. Data are represented as individual points for each subject, overlaid by a horizontal mean group value ± SEM. Statistically significant differences are indicated as * for \( p < 0.05 \), ** for \( p < 0.01 \), *** for \( p < 0.001 \) and **** for \( p < 0.0001 \).

pronounced in female KO mice (Figure 6A). Experimental murine models suggest that apoptosis constitutes an early event in SS (22), which is consistent with the pronounced effect in female mice as early as at 7 months of age.

**Female ERdj5−/− Mice Have Reduced Salivary Gland Function**

We tested the salivary gland function in our experimental model following pilocarpine stimulation. Saliva flow rate was significantly reduced in 12 months old female KO vs. WT (\( t \)-test \( p = 0.0452 \)), while no significant difference was observed in the male animals of the same age (Figure 6B).

**DISCUSSION**

The present study provides evidence for the involvement of the ER Quality Control system (ERQC) in the SGs in the context of Sjögren's syndrome. Specifically, we demonstrate that ERdj5 is involved in the pathophysiology of pSS and that ERdj5−/− mice constitute the first described ER-stress related model of SS, manifesting a plethora of the established traits of the disease.

**ERdj5 Is Involved in the Pathophysiology of SS in Human Patients**

As is evident from previous studies, ER-stress can contribute to the pathophysiology of SS. We have previously demonstrated that ERdj5 is a key regulator of the UPR through the PERK axis, inhibiting the phosphorylation of eIF2α by inactivating PERK (17). Another UPR axis involved in LSGs of SS patients is the IRE1α/XBP1 pathway (12). In our study, we have indeed confirmed the upregulation of spliced (activated) XBP1 within the salivary glands of SS patients along with the upregulation of ERdj5, a key ERQC element. The sensor and mediator of these pathways, BiP, has been shown to be selectively expressed in the acinar and ductal epithelial cells in the MSGs (23), while ER-stress induction in a human SG epithelial cell line in vitro caused XBP1 mediated autophagy, which was argued to be a protective mechanism against autoantigen re-localization due to apoptotic cell death (11). Moreover, an XBP1 mediated up-regulation of Ro52, which participates in the quality control of IgG1 has been demonstrated in epithelial cells of SS patient LSGs (24). This finding suggests a possible mechanism for the involvement of the ER-stress machinery in autoimmune conditions. Since targets of XBP1s include known SS related autoantigens, it stands to reason that the activation of this branch of the UPR may lead to an increased presence of molecules with autoantigenic potential, their subsequent recognition by the immune system and the establishment and perpetuation of inflammation. Additionally, ER-stress can interfere with antigen presentation, as has been the case in XBP1 mediated miR-346 induction. This microRNA regulates immune responses by targeting genes of the major histocompatibility complex (MHC) class I, interferon-induced genes, and the ER antigen peptide transporter 1 (TAP1), which is necessary for proper MHC class I- associated antigen presentation (25). As it is unclear whether ER-stress precedes or follows the establishment of the SS pathology, it is important to recognize that it can be induced by transcription factors and the action of cytokines involved in other cellular stress events, like oxidative stress and nucleolar stress. The latter may also result in ribosomal and translational stress causing ER-stress in turn. All those stress
FIGURE 5 | Inflammatory cytokine levels in murine serum and in SG tissue protein extracts from male and female animals of three age groups (1.5, 7, and 12 m.o.). Samples were analyzed with the Multiplex immunoassay magnetic bead technology. (A) Quantitative identification of IL-18, IL-23, and IL-17A in the serum. (B) Quantitative identification of IL-18, IL-23, and IL-10 in the SG tissue. In all charts, data are represented as individual points for each subject, overlaid by a horizontal mean group value ± SEM, with statistically significant differences indicated as * for \( p < 0.05 \), ** for \( p < 0.01 \) and *** for \( p < 0.001 \).

pathways crosstalk with NFκB signaling, making them relevant to inflammatory responses (26, 27).

The higher ERdj5 signal in SG biopsies from pSS patients highlights its involvement in the pathological manifestations of SS. The predominant expression of ERdj5 in the epithelial compartment of MSGs is consistent with the fact that epithelial cells possess a central role in SS: They are intrinsically activated, expressing inflammatory mediators and specific, traditionally expressed in immune cells, adhesion molecules, and receptors (28), and act both as targets and orchestrators of local autoimmune inflammatory responses, hence the etiological name of SS as “autoimmune epithelitis” (29).

By their nature, chaperone proteins can associate with other proteins, including autoantigens, and can act as recruiting agents in antigen presentation pathways (30). Calreticulin in particular, has been found to participate in antigen presentation of the Ro60 epitopes (31). Additionally, many ER chaperones can be detected in the serum, and some of them have been shown to act as autoantigens themselves, with autoantibodies against BiP (32), HSP47 (33), calreticulin (34), calnexin (35), and GRP94 (34, 35) documented in autoimmune diseases. While ERdj5 could be a new addition to this list of antigenic molecules, the effect of its ablation in mice suggests a more indirect role: The overexpression of ERdj5 in SS patients could be related to a protective mechanism and a compensatory effort of the remaining intact epithelium to produce the necessary proteins. Indeed, the upregulation of the IRE1α/XBP1 branch of the UPR in SS patients, reported in previous studies (12, 24) and confirmed in our experiments, supports this model. Such a connection between ERAD proteins and autoimmunity has been documented in the function of HRD1/synoviolin in synovial cells in RA (36). Also, the inability of the ER to cope with protein misfolding leading to immune reactions is prevalent in HLA-B27 misfolding and augmented production of IL-23 in experimental models of spondyloarthritis (37) as well as in ankylosing spondylitis (38). This could provide a paradigm related to the observed connection between ERdj5 and autoimmunity. Our data indicate ER-stress as the underlying
Apostolou et al. ERdj5 Is Involved in Sjögren’s Syndrome

FIGURE 6 | (A) TUNEL assay in murine salivary gland tissue sections. Representative images from TUNEL staining (red) in female ERdj5−/− and wildtype animals of 7 and 12 months old. The nuclei were stained with DAPI (blue). ERdj5−/− animals had positive signal within the inflammatory areas. Objective magnification: 20x. (B) Functional assay of saliva flow in 12 months old mice. Measurements shown in µL of saliva per minute per g of animal body weight. Data are represented as individual points for each subject, overlaid by a horizontal mean group value ± SEM. The statistically significant difference is indicated as * for p = 0.045.

connection that explains the counterintuitive finding of ERdj5 upregulation in patients and the autoimmune responses in mice with ERdj5 ablation. The activation of the IRE1α/XBP1 axis of the UPR in patients and the activation of the same branch of the UPR in the salivary glands of ERdj5−/− mice, that has been demonstrated in previous studies (19), support this idea.

The ERdj5−/− Mouse: A Potent Animal Model of SS

The pathology that arises in ERdj5−/− mice is induced at an early state and closely resembles multiple facets of the human disease. In this study we have characterized the phenotypic traits of this animal model, which include SG inflammatory infiltrates, serum autoantibodies, reduced saliva secretion, excessive cell death, and deregulated cytokine levels within the SG tissue and in the serum, all with higher severity in females. The importance of a potent animal model for the study of SS is highlighted by the numerous studies that have aimed to develop or describe models of the disease. We believe that ERdj5−/− mice are a valuable addition in the list of available tools for the study of SS, as they are positive for a plethora of features of SS that ideally should be fulfilled by an animal model (39), like few other described models are. The phenotypic characteristics of our experimental model are summarized, along with previously described animal models of SS, in Table 2 (40–49).

The spontaneous development of inflammatory infiltrations involved mostly epithelial sites. This development of periductal inflammation in SGs of ERdj5−/− mice was reminiscent of inflammatory lesions in MSGs of SS patients, consisting mainly of B and T lymphocytes. In our experimental model, like in previously described murine models of SS, the inflammatory infiltrates evolve in size over age. The cellular composition of those infiltrates remained similar though at all time-points. Lesions in the SGs were accompanied by higher titers of ANAs systemically, with the titer of ANAs being positively correlated to the extent of the inflammation and the number of lesion foci. Autoantibodies are a defining and diagnostic trait of SS pathology, present in many previously described models of the disease. Our mouse model exhibited higher levels of anti-SSA/Ro52 and antiSSA/Ro60 antibodies in females at the age of 7 months, and higher levels of anti-SSB/La antibodies in females at 12 months of age, providing clues for a possible trend that is not easily discernable in human patients who are usually diagnosed when the disease is already established: High anti-SSA/Ro52+60 antibodies might be a trait of early disease stages, while the anti-SSB/La antibodies may have delayed elevation with respect to disease development. Furthermore, even in wildtype animals, these autoantibodies increase naturally with age, so the age choice of an experimental setup may mean the difference between a negative or a positive result regarding these markers. Interestingly, males did not differ at any age point regarding anti-SSA/Ro52+60 autoantibodies, while at 12 months of age we observed reduced anti-SSB/La autoantibodies. More experimentation is required for the interpretation of this result, which could be due to masking by anti-idiotypic antibodies as has been reported to occur specifically for anti-SSB/La antibodies (50), complex formation, and serum depletion, or other regulatory mechanisms.

Chronic inflammation and ensuing tissue damage in SS patients eventually leads to compromised SG function and xerostomia. Reduced salivary function was confirmed in female ERdj5−/− mice, evident by the decreased production of saliva, adding to the traits of this model that are relevant to SS. Importantly, this effect was noted in the experimental
### TABLE 2 | Phenotypic characteristics of ERdj5−/− mice and other mouse SS models.

| Phenotype | Inflammatory infiltrates in SG | SG tissue damage | Serum AutoAbs | Salivary hypofunction | Female predilection | Cytokines in serum | Cytokines in SGs | Parenchymal inflammation | Other phenotypes |
|-----------|-------------------------------|-----------------|---------------|---------------------|---------------------|--------------------|-------------------|----------------------|-------------------|
| Knock-out | ERdj5 KO                      | + B-cells, T-cells (2:1 ratio) | + in females | Anti-Ro, Anti-La | Elevated IL-2, IL-18 | Elevated IL-23, IL-10 | Kidney, occasional infiltrations in liver | Lachrymal gland inflammation and hypofunction. Tumor in numerous organs. Late onset of SS-like phenotype. Skin lesions by over-scratching |
|           |                               |                 |               |                     |                     |                    |                   |                     |                   |
|           | Id3 KO                        | + IFN-γ and IL-4 producing lymphocytes | + Anti-Ro, Anti-La, Autoantibodies to ductal cells | + | nd | nd | nd | Occasional infiltrations in kidney and lung | Lachrymal gland inflammation, apoptosis, and hypopfunction. Periodic dermatitis. Conjunctivitis, Splenomegaly. Lymphadenopathy. Elevated serum IgGs |
|           |                               |                 |               |                     |                     |                    |                   |                     |                   |
|           | Ilkβ ζ KO                     | -               | -             | + Anti-Ro, Anti-La | nd | nd | nd | Interstitial pneumonia | Lachrymal gland inflammation, apoptosis, and hypopfunction. Persistent dermatitis. Conjunctivitis, Splenomegaly. Lymphadenopathy. Elevated serum IgGs |
|           |                               |                 |               |                     |                     |                    |                   |                     |                   |
| Transgenic | BAFF                          | + B-cells predominantly | - for Anti-Ro, - for Anti-La | + | - | nd | nd | Late onset nephritis. Occasional lung, liver infiltrations | SLE-like, SS-like with age. Reduction in Tregs. Germinal centers in SGS. Hyperactive B-cells |
| overexpression | IL-12 in SJL strain         | + | nd | + ANAs, Anti-La | + | + | nd | Lung inflammation | Lachrymal gland inflammation, Mild autoimmune thyroiditis. Affecting osmoregulation of SGS |
| Chimeric | SS PBMCs in NOD-scid IL-2γ (null) | + CD4 predominantly | nd | nd | + | nd | Elevated IFN-γ, IL-10, IL-17, IL-2, IL-6, TNFa | nd | Type-I diabetes. Lachrymal gland inflammation |
| Spontaneous | MRL/lpr                      | + IFN-γ and IL-17 producing CD4 + | nd | nd | + | nd | nd | nd | SLE: Lachrymal gland inflammation, Early death. Aggressive autoimmune lymphoproliferative disorder |
| models | NOD                           | Dynamic CD4+ PD1+ FOXP3-, mainly Th1 | + | + Anti-Ro, Anti-La | - | - for SG, - for lachrymal | + | + IFNs, IL-10, IL-17, IL-12p40 | Lung inflammatory infiltrations. Kidney autoantibody deposition |
|           | NOD Aec1, Aec2                | Progressive T-cell and B-cell infiltrations | + | + | + | Differentialy expressed ± IFNs | ± IFNs, Elevated cytokines | nd | Anti-M3R antibodies. Lachrymal gland hypofunction in females | (Continued) |
Inflammatory infiltrates in SG

| Phenotype            | Salivary hypofunction | Female predilection | Serum AutoAbs | Cytokines in serum | Cytokines in SGs | Parenchymal inflammation |
|----------------------|-----------------------|---------------------|---------------|-------------------|-----------------|--------------------------|
| Incomplete Freund's adjuvant IP injection | +                     | nd                  | +             | +                 | Augmented by F.adP. injection | +                       |
| PolyI:C injection    | +                     | +                   | +             | +                 | Augmented by F.adP. injection | +                       |
| NZB/NZW F1 Augmented by incomplete Freund's adjuvant IP injection | +                     | +                   | +             | +                 | Augmented by F.adP. injection | +                       |
| Alum injection       | +                     | +                   | +             | +                 | Augmented by F.adP. injection | +                       |
| NOD2758              | +                     | +                   | +             | +                 | Augmented by F.adP. injection | +                       |

SS tissue damage

| Inflammatory infiltrates in SG | Serum AutoAbs | SJögren's Syndrome damage |
|-------------------------------|---------------|---------------------------|
| NZB/NZW F1                   | +             | +                         |
| Alum in BALB/c                | +             | +                         |
| NOD2758                       | +             | +                         |

+ SS that is reported in the relevant literature; nd, not determined in the relevant literature; italics, trait discussed as possibility but not shown in experimental data.

In summary, ERdj5, as part of the ER quality control machinery, may be considered a key player in maintaining the integrity of the salivary gland, a tissue that is prone to damage, which leads to the detrimental effects of initiation and perpetuation of autoimmune group with the most extensive inflammatory lesions, higher number of inflammatory foci, higher titers of ANAs, and anti-SSB/La antibodies in the blood serum. In patients, SS can be accompanied by parenchymal organ involvement, in the form of autoimmune epithelitis (29). Accordingly, limited individuals in our study developed small inflammatory lesions in the liver, and aged ERdj5−/− animals had a marked inflammation in the renal pelvis (not shown). An interesting observation is the sex related difference in the severity of the SS-like phenotype in ERdj5−/− animals, which is more pronounced in female mice. In humans, SS has a strong predilection for women (9:1 female to male ratio) (48). This makes the ERdj5−/− mouse an appropriate model for the study of the human disease.

In ERdj5−/− mice, similarly to SS patients (51), deregulated expression of cytokines has been identified both systemically and within the SGs. IL-23, which, synergistically with IL-18, induces additional proinflammatory cytokines (28) was found in higher levels both in the serum and the SGs of female 12 month old animals, a result consistent with findings in SS patients (52). The higher IL-23 levels were accompanied by serum IL-18 upregulation in the experimental group with the most prominent inflammation and the highest ANA and anti-SSB/La titer, the 12 months old female knockouts. Indeed, in SS, IL-18 has been associated with tissue pathogenesis and the presence of anti-SSA/Ro and anti-SSB/La antibodies (53). In the young KO females, IL-10 was lower in the SG compared to age-matched WT females, while this trend reversed in aged female animals. This finding can be attributed to IL-10’s documented dual role. At early stages, lower levels of IL-10 fail to achieve its anti-inflammatory action. Inversely, IL-10 has been documented to act pro-inflammatory in the presence IFN-α (54), and thus its higher levels in aged female animals could contribute to the lesion progression. The fact that elevated IL-10 levels in SS patients have been correlated with disease severity (51) is consistent with our data, since patients are examined when the disease is already established.

The high occurrence of cell death observed within the severe inflammatory lesions of ERdj5−/− mice agrees with previous clinical (55) and experimental studies (43) and can provide a plausible mechanism for the exposure of autoreactive material to the extracellular space that drives the initiation and the perpetuation of the inflammatory process. Autoantibodies from sera of SS patients are known to be able to activate apoptotic pathways (56). Consistently, our mouse model presented with elevated ANAs and anti-SSB/La antibodies in the groups with increased cell death. Supporting evidence come also from the upregulation of the caspase-induced cytokine IL-18 in the serum of female ERdj5−/− mice, which is found elevated in the saliva of SS models and human SS MSGs (53).

**CONCLUSIONS**

In summary, ERdj5, as part of the ER quality control machinery, may be considered a key player in maintaining the integrity of the salivary gland, a tissue that is prone to damage, which leads to the detrimental effects of initiation and perpetuation of autoimmune
responses. Even though the triggering mechanism(s) are yet unknown, deregulated ER-stress may contribute to the cascades that lead to tissue destruction, antigen presentation and sustained chronic inflammation, making it harder for the tissue to heal itself, ensure integrity and evade triggering autoimmune responses.

**DATA AVAILABILITY**

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

**AUTHOR CONTRIBUTIONS**

EA and PM contributed equally in this work. They mutually designed and performed all the experiments and authored the manuscript. TI created the ERdj5 knockout mouse model and critically reviewed the manuscript. AT and GS contributed equally, supervising the design and execution of all experimental procedures, critically reviewing and proofing the manuscript.

**REFERENCES**

1. Vincenz-Donnelly L, Hipp MS. The endoplasmic reticulum: a hub of protein quality control in health and disease. *Free Radiol. Biomed.* (2017) 108:383–93. doi: 10.1016/j.freeradiobiomed.2017.03.031
2. Frakes AE, Dillin A. The UPRER: sensor and coordinator of organ ischemia homeostasis. *Mol Cell.* (2017) 66:761–71. doi: 10.1016/j.molcel.2017.05.031
3. Navid F, Colbert RA. Causes and consequences of endoplasmic reticulum stress in rheumatic disease. *Nat Rev Rheumatol.* (2017) 13:25–40. doi: 10.1038/nrrheum.2016.192
4. Martins AS, Alves I, Helguero L, Domingues MR, Neves BM. The unfolded protein response in homeostasis and modulation of mammalian immune cells. *Int Rev Immunol.* (2016) 35:457–76. doi: 10.3109/08830185.2015.1110151
5. Baccelti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases. *J Mol Biol.* (2014) 92:583–94. doi: 10.1007/s00109-014-1150-5
6. Cao SS, Luo KL, Shi L. Endoplasmic reticulum stress interacts with inflammation in human diseases. *J Cell Physiol.* (2016) 231:288–94. doi: 10.1002/jcp.25098
7. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. *Cell.* (2008) 134:743–56. doi: 10.1016/j.cell.2008.07.021
8. Watkins LR, Jessen B, Wiszniewski W, Vece TJ, Jan M, Sha Y, et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. *Nat Genet.* (2015) 47:654–60. doi: 10.1038/ng.3279
9. Papageorgiou A, Voulgarelis M, Tzioufas AG. Clinical picture, outcome and predictive factors of lymphoma in Sjögren syndrome. *Autoimmun Rev.* (2015) 14:641–9. doi: 10.1016/j.autrev.2015.03.004
10. Barrera MJ, Aguileras S, Castro I, Cortes J, Bahamondes V, et al. Pro-inflammatory cytokines enhance ERAD and ATF6alpha pathway activity in salivary glands of Sjögren’s syndrome patients. *J Autoimmun.* (2016) 75:68–81. doi: 10.1016/j.jaut.2016.07.006
11. Skopouli FN, Katsiougiannis S. How stress contributes to autoimmunity—lessons from Sjögren’s syndrome. *FEBS Lett.* (2018) 592:5–14. doi: 10.1016/1873-3468.12933
12. Sepulveda D, Barrera MJ, Castro I, Aguileras S, Carvajal P, Lagos C, et al. Impaired ATF6alpha/XBP1 pathway associated to DNA methylation might contribute to salivary gland dysfunction in Sjögren’s syndrome patients. *Rheumatology.* (2018) 57:1021–32. doi: 10.1093/rheumatology/key021
13. Cunnea PM, Miranda-Vizuete A, Bertoli G, Simmen T, Damdinopoulos AE, Hermann S, et al. ERdj5, an endoplasmic reticulum (ER)-resident protein containing DnaJ and thioredoxin domains, is expressed in secretory cells or following ER stress. *J Biol Chem.* (2003) 278:1059–66. doi: 10.1074/jbc.M206995200
14. Ushioda R, Hoseki J, Araki K, Jansen G, Thomas DY, Nagata K. ERdj5 is required as a disulfide reductase for degradation of misfolded proteins in the ER. *Science.* (2008) 321:569–72. doi: 10.1126/science.1159293
15. Ushioda R, Miyamoto A, Inoue M, Watanabe S, Okumura M, Maegawa KI, et al. Redox-assisted regulation of Ca2+ homeostasis in the endoplasmic reticulum by disulfide reductase ERdj5. *Proc Natl Acad Sci USA.* (2016) 113:E6055–e63. doi: 10.1073/pnas.1605818113
16. Oka OR, Pringle MA, Schopp IM, Braakman I, Bulleid NJ. ERdj5 is the ER reductase that catalyzes the removal of non-native disulfides and correct folding of the LDL receptor. *Mol Cell.* (2013) 50:793–804. doi: 10.1016/j.molcel.2013.05.014
17. Thomas CG, Spyrou G. ERdj5 sensitizes neuroblastoma cells to endoplasmic reticulum stress-induced apoptosis. *J Biol Chem.* (2009) 284:6282–90. doi: 10.1074/jbc.M806189200
18. Ushioda R, Hoseki J, Nagata K. Glycosylation-independent ERAD pathway serves as a backup system under ER stress. *Mol Biol Cell.* (2013) 24:3155–63. doi: 10.1091/mbc.e13-03-0138
19. Hosoda A, Tokuda M, Akai R, Kohno K, Iwaski T. Positive contribution of ERdj5/JPDI to endoplasmic reticulum protein quality control in the salivary gland. *Biochem J.* (2009) 425:117–25. doi: 10.1042/BJ20091269
20. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carson SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis.* (2002) 61:554–8. doi: 10.1136/ard.61.6.554
21. Christodoulou MJ, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. *J Autoimmun.* (2010) 34:400–7. doi: 10.1016/j.jaut.2009.10.004
22. Kramer JM. Early events in Sjogren’s Syndrome pathogenesis: the importance of innate immunity in disease initiation. *Cytokine.* (2014) 67:92–101. doi: 10.1016/j.cyto.2014.02.009
23. Katsiougiannis S, Tenta R, Skopouli FN. Endoplasmic reticulum stress causes autophagy and apoptosis leading to cellular redistribution of the autoantigens Ro/Sjögren’s syndrome-related antigen A (SSA) and La/SSB in salivary gland.
epithelial cells. *Clin Exp Immunol.* (2015) 181:244–52. doi: 10.1111/cei.12638

24. Takahata M, Bohgaki M, Tsukiyama T, Kondo T, Asaka M, Hatakeyama S. Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. *Mol Immunol.* (2008) 45:2045–54. doi: 10.1016/j.molimm.2007.10.023

25. Bartoszewski R, Brewer JW, Rab A, Crossman DK, Bartoszewska S, Kapoor N, et al. The unfolded protein response (UPR)-activated transcription factor X-box-binding protein 1 (XBP1) induces microRNA-346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA and governs immune regulatory genes. *J Biol Chem.* (2011) 286:41862–70. doi: 10.1074/jbc.M111.304956

26. Chen J, Lobd IT, Morin P, Novo SM, Simpson J, Kennerknecht K, et al. Identification of a novel TIF-IA-NF-kappaB nuclear stress response pathway. *Nucleic Acids Res.* (2018) 46:6188–205. doi: 10.1093/nar/gky545

27. Schmitz ML, Shaban MS, Albert BV, Gokcen A, Kracht M. The crosstalk of endoplasmic reticulum (ER) stress pathways with NF-kappaB: complex mechanisms relevant for cancer, inflammation and infection. *Biomedicines.* (2018) 6:E58. doi: 10.3908/biomedicines060058

28. Goules AV, Kapsokefalou EK, Tzioufas AG. Insight into pathogenesis of Sjögren's syndrome: dissection on autoimmune infiltrates and epithelial cells. *Clin Immunol.* (2017) 182:30–40. doi: 10.1016/j.clim.2017.03.007

29. Moussopoulos HM, Sjögren's syndrome: autoimmune epithelitis. *Clin Immunol Immunopathol.* (1994) 72:162–5. doi: 10.1006/clin.1994.1123

30. Morito D, Nagata K. ER Stress proteins in autoimmune and inflammatory diseases. *Front Immunol.* (2012) 3:84. doi: 10.3389/fimmu.2012.00048

31. Staikou EV, Routsias JG, Makri AA, Terzoglou A, Sakarellos-Datisiotis M, Sakarellos C, et al. Calreticulin binds preferentially with B cell linear epitopes of Ro60 kDa autoantigen, enhancing recognition by anti-Ro60 kDa autoantibodies. *Clin Exp Immunol.* (2003) 134:143–50. doi: 10.1046/j.1600-2249.2003.02246.x

32. Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Weoley P, et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. *J Immunol.* (2001) 166:1492–9. doi: 10.4049/jimmunol.166.3.1492

33. Fujimoto M, Hamaguchi Y, Yazawa N, Komura K, Takehara K, Sato S. Autoantibodies to a collagen-specific molecular chaperone, heat-shock protein 47, in systemic sclerosis. *Clin Exp Immunol.* (2004) 138:534–9. doi: 10.1111/j.1365-2249.2004.02633.x

34. Boehm J, Orth T, Van Nguyen P, Soling HD. Systemic lupus erythematous is associated with increased auto-antibody titers against calreticulin and grp94, but calreticulin is not the Ro/SS-A antigen. *Eur J Clin Invest.* (1994) 24:248–57. doi: 10.1111/j.1365-2362.1994.tb01082.x

35. Weber CK, Hasbeck M, Engbrecht M, Schernt B, Mielenz D, Graef D, et al. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematous. *Rheumatology.* (2008) 49:2255–63. doi: 10.1093/rheumatology/keq272

36. Amano T, Yamasaki S, Yagishita N, Tsuchimochi K, Shin H, Kawahara K, et al. Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjogren's syndrome. *J Immunol.* (2005) 175:8409–14. doi: 10.4049/jimmunol.175.12.8409

37. Okuma A, Hoshino K, Ohba T, Fukushima S, Aiba S, Akira S, et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjogren's syndrome-like autoimmune disease. *Immunity.* (2013) 38:450–60. doi: 10.1016/j.immuni.2012.11.016

38. Ohyama Y, Carroll VA, Deshmukh U, Gaskin F, Brown MG, Fu SM. Severe focal sialoadenitis and dacyrooadenitis in NZM2328 mice induced by MCMV: a novel model for human Sjögren's syndrome. *J Immunol.* (2006) 177:7391–7. doi: 10.4049/jimmunol.177.10.7391

39. Jonsson MV, Delaleu N, Jonsson R. Animal models of Sjogren's syndrome. *Clin Exp Immunol.* (2015) 182:14–23. doi: 10.1111/cei.12638

40. Colbert RA, Tran TM, Layh-Schmitt G. HLA-B27 as a novel model for human Sjögren's syndrome. *J Immunol.* (2006) 177:7391–7. doi: 10.4049/jimmunol.177.10.7391

41. Scofield RH, Asfa S, Obeso D, Jonsson R, Kurien BT. Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjogren's syndrome. *J Immunol.* (2005) 175:8409–14. doi: 10.4049/jimmunol.175.12.8409

42. Peck AB, Nguyen CQ. What can Sjogren's syndrome-like disease in mice contribute to human Sjögren's syndrome? *Clin Immunol.* (2017) 182:14–23. doi: 10.1016/j.clim.2017.03.001

Conflict of Interest Statement: AT has received research grants from Novartis, Pfizer, UCB, AbbVie and GSK pharmaceutical companies, through the National and Kapodistrian University of Athens, outside the submitted work.

The funder played no role in the study design, the collection, analysis or interpretation of data, the writing of this paper or the decision to submit it for publication.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Apostolou, Moustardas, Iwawaki, Tzioufas and Spyrou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is prohibited which does not comply with these terms.